HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account
Stanford Research Institute creating an anti-angiogenic model for multiple myeloma
Posted: Oct 19, 2013
Stanford Research Institute creating an anti-angiogenic model for multiple myeloma image

A friend sent me this link to Stanford Research Institute's work in the development of an anti-angiogenic molecule, SR16388. Studies show that this molecule prevents angiogenesis (or new blood vessel development) and the growth of multiple myeloma cells. The new molecule is currently under development and is getting ready for early patient clinical trials. Click Here to read the SRI International article.

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd). 

More on New in Myeloma

Faster and More Efficient Stem Cell Collection with FDA Approved APHEXDA image
Faster and More Efficient Stem Cell Collection with FDA Approved APHEXDA
A Delicate Topic: Who Gets CAR-T? image
A Delicate Topic: Who Gets CAR-T?
Elranatamab Receives FDA Accelerated Approval for Refractory/Relapsed Myeloma Treatment image
Elranatamab Receives FDA Accelerated Approval for Refractory/Relapsed Myeloma Treatment
Talquetamab Approved for Myeloma Patients by FDA image
Talquetamab Approved for Myeloma Patients by FDA
A Promising New CAR-T Therapy on the Horizon image
A Promising New CAR-T Therapy on the Horizon
Single Cell Sequencing in Myeloma image
Single Cell Sequencing in Myeloma
See More

Trending Articles

Kappa and Lambda Light Chains Kappa and Lambda Light Chains
The Best Time to Take Dexamethasone and Why The Best Time to Take Dexamethasone and Why
The Innovation of Myeloma in the 2020s and Beyond The Innovation of Myeloma in the 2020s and Beyond
The Innovation of Myeloma in the 2000s and 2010s The Innovation of Myeloma in the 2000s and 2010s
What is the Prognosis of a Multiple Myeloma Patient? What is the Prognosis of a Multiple Myeloma Patient?

Upcoming Events

Different Forms of Advocacy and How You Can Get Involved

Different Forms of Advocacy and How You Can Get Involved

Sep 26 / 14:00 EDT
Nonsecretory Myeloma, Plasmacytomas, and Other Things

Nonsecretory Myeloma, Plasmacytomas, and Other Things

Oct 12 / 13:00 EDT
Seattle Myeloma Roundtable

Seattle Myeloma Roundtable

Oct 14 / 8:00 PDT

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Abbvie
Genentech
GSK
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube

Charity Navigator https://www.guidestar.org/profile/45-5354811

HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.

Copyright © 2023 HealthTree Foundation. All rights reserved.

Tax ID 45-5354811